Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
140 pending office actions • 52 art units • 117 examiners • 0 of 140 (0%) have an AI response strategy ready • 117 patents granted in the last 365 days
Amgen Inc. maintains a portfolio of 143 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 119 distinct examiners and 43 distinct art units. This distribution indicates a large and technically diverse portfolio with a significant number of examiners handling multiple matters.
The busiest examiner is SKELDING, ZACHARY S, who is currently handling 4 pending office actions. While there are 119 distinct examiners involved, the 143 pending office actions are concentrated enough that some examiners handle multiple files. The 43 distinct art units involved suggest that the company's technology spans many specialized groups within the biological and pharmaceutical fields. Practitioners must manage 143 pending office actions by tailoring strategies to the specific requirements of 43 distinct art units. This level of activity across 119 distinct examiners requires careful coordination to maintain consistency in the company's overall patent strategy. The involvement of 119 distinct examiners highlights the importance of understanding individual examiner behavior across the 143 pending office actions.
Based on the USPTO statutory response window for each pending office action. 37 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 37 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (1%) |
| §101 + other | 11 (8%) |
| §103 only | 29 (21%) |
| §102 only | 5 (4%) |
| §112 only | 13 (9%) |
| Double-patenting only | 4 (3%) |
| Double-patenting + other | 26 (19%) |
| Multi-statute (no §101) | 47 (34%) |
| No statute on record | 4 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKELDING, ZACHARY S | 4 | 59.8% | +41.1% |
| BRISTOL, LYNN ANNE | 3 | 63.4% | +39.8% |
| DUFFY, BRADLEY | 3 | 54.4% | +46.0% |
| TECCO, ANDREW M | 2 | 65.5% | +24.6% |
| BOUCHELLE, LAURA A | 2 | 80.2% | +10.7% |
| PATEL, SHEFALI DILIP | 2 | 58.0% | +27.6% |
| SEIF, DARIUSH | 2 | 70.6% | +6.1% |
| HALL, DEANNA K | 2 | 75.6% | +15.3% |
| BANERJEE, KOYELI | 2 | 50.0% | +0.0% |
| FREHE, WILLIAM R | 2 | 59.9% | +42.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17846310 | SYRINGES, ASSEMBLIES, AND METHODS OF MANUFACTURE | BOUCHELLE, LAURA A | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18018389 | CELL CULTURE MEDIA AND METHODS OF MAKING AND USING THE SAME | VAN BUREN, LAUREN K | 153d overdue |
| 17775386 | Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules | SKELDING, ZACHARY S | 52d overdue |
| 18270581 | USE OF KRAS G12C INHIBITOR IN TREATING CANCERS | HASTINGS, ALISON AZAR | 23d overdue |
| 18562107 | SOTORASIB DOSING REGIMEN | CHANDRAKUMAR, NIZAL S | 18d overdue |
| 17436218 | IN VIVO REVERSIBILITY OF HIGH MOLECULAR WEIGHT SPECIES | FRITCHMAN, REBECCA M | 8d |
| 18266689 | DIFFUSION GRADIENT ASSAY FOR ANTI-CD3-CONTAINING MOLECULES | SPENCE, JENNIFER SUZANNE | 12d |
| 18038579 | ENANTIOSELECTIVE ALKENYLATION OF ALDEHYDES | MOORE, SUSANNA | 16d |
| 17923347 | Deep Learning Platforms for Automated Visual Inspection | HICKS, AUSTIN JAMES | 22d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042267 | ANTIGEN BINDING PROTEINS WITH NON-CANONICAL DISULFIDE IN FAB REGION | BRISTOL, LYNN ANNE | 93d overdue |
| 16586318 | CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS | SKELDING, ZACHARY S | 77d overdue |
| 17775386 | Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules | SKELDING, ZACHARY S | 52d overdue |
| 17775063 | ENGINEERING CHARGE PAIR MUTATIONS FOR PAIRING OF HETERO-IgG MOLECULES | DUFFY, BRADLEY | 45d overdue |
| 18962768 | AUTOMATED SYSTEMS AND METHODS FOR FOIL PACKAGING COMPONENTS | TECCO, ANDREW M | — |
| 18845286 | PACKAGING FOR DRUG DELIVERY DEVICE | TECCO, ANDREW M | — |
| 18789085 | DRUG DELIVERY DEVICE | BOUCHELLE, LAURA A | — |
| 18674549 | INJECTION DEVICE FOR DRUG DELIVERY AND PACKAGING FOR THE INJECTION DEVICE | PATEL, SHEFALI DILIP | — |
| Art Unit | Apps |
|---|---|
| 3783 | 27 |
| 1643 | 10 |
| 1674 | 8 |
| 1641 | 7 |
| 1644 | 6 |
| 1675 | 4 |
| 1642 | 4 |
| 1647 | 4 |
| 1622 | 3 |
| 3731 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19281019 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | SIMMONS, CHRIS E | 1622 | §112Other | Non-Final OA | 75d | Pending | Jul 25, 2025 |
| 19045308 | ROBOTIC SYSTEM FOR PERFORMING PATTERN RECOGNITION-BASED INSPECTION OF PHARMACEUTICAL CONTAINERS | RODRIGUEZ, JOSEPH C | 3653 | §103Other | Non-Final OA | — | Pending | Feb 04, 2025 |
| 18878828 | ANTI-PD-1 ANTIBODY FORMULATIONS | OGUNBIYI, OLUWATOSIN A | 1645 | §103§112 | Non-Final OA | — | Pending | Dec 24, 2024 |
| 18967331 | METHODS OF TREATING HEART FAILURE BY ADMINISTERING OMECAMTIV MECARBIL | COHEN, MICHAEL P | — | §112 | Non-Final OA | — | Pending | Dec 03, 2024 |
| 18962768 | AUTOMATED SYSTEMS AND METHODS FOR FOIL PACKAGING COMPONENTS | TECCO, ANDREW M | 3731 | §102§103 | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18939822 | PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR | O DELL, DAVID K | 1621 | DP | Non-Final OA | — | Pending | Nov 07, 2024 |
| 18934755 | SUSTAINABLE AND MODULAR PACKAGING SYSTEMS FOR CONTAINERS FOR PHARMACEUTICAL USE | ORTIZ, RAFAEL ALFREDO | 3736 | §103§112 | Non-Final OA | — | Pending | Nov 01, 2024 |
| 18855457 | COMPLEMENT-DEPENDENT CYTOTOXICITY METHODS | CURRENS, GRANT CARSON | 1651 | §103 | Non-Final OA | — | Pending | Oct 09, 2024 |
| 18853736 | Cancer Treatments Using MTA-Cooperative PRMT5 Inhibitors | MCKOY, QUINCY ANDRE | 1626 | §103§112DP | Non-Final OA | — | Pending | Oct 03, 2024 |
| 18853977 | SYSTEMS AND METHODS FOR REDUCING EXCESS RESOURCE USAGE | KESSLER, GREGORY AARON | 2197 | §101§102 | Non-Final OA | — | Pending | Oct 03, 2024 |
| 18845286 | PACKAGING FOR DRUG DELIVERY DEVICE | TECCO, ANDREW M | 3731 | §102§103§112 | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18845273 | OPTIMIZED TRANSFECTION PROTOCOL | CORDAS, EMILY ANN | 1632 | §103 | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18842194 | A PROCESS FOR PREPARING 4-METHYL-2-PROPAN-2-YL-PYRIDINE-3-CARBONITRILE | RAHMANI, NILOOFAR | 1691 | Other | Final Rejection | — | Pending | Aug 28, 2024 |
| 18807705 | MACHINE LEARNING (ML)-BASED SYSTEMS AND METHODS FOR PREDICTING DISEASE | EVANS, ASHLEY ELIZABETH | 3687 | §101§103 | Non-Final OA | 39d | Pending | Aug 16, 2024 |
| 18798878 | AFLIBERCEPT ATTRIBUTES AND METHODS OF CHARACTERIZING AND MODIFYING THEREOF | BORGEEST, CHRISTINA M | 1675 | §101§102§103§112 | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18789085 | DRUG DELIVERY DEVICE | BOUCHELLE, LAURA A | 3783 | §102§103Other | Non-Final OA | — | Pending | Jul 30, 2024 |
| 18832887 | SYNTHESIS OF A KIF18A INHIBITOR | OH, TAYLOR V | 1625 | §102§112 | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18730357 | Crystalline Forms Of An MCL-1 Inhibitor | SAMSELL, RILLA MARIE | 1624 | §102§103§112 | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18730353 | Crystalline Salt and Solvate Forms Of Murizatoclax (AMG 397) | DAHLIN, HEATHER RAQUEL | 1629 | §103§112DP | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18770259 | ASGR INHIBITORS | HOWARD, ZACHARY C | 1674 | §102§103§112 | Non-Final OA | — | Pending | Jul 11, 2024 |
| 18744036 | AUTOINJECTOR WITH SHOCK REDUCING ELEMENTS | MEDWAY, SCOTT J | 3783 | §102§103 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18719164 | METHODS FOR DESIGNING AND PERFORMING A VAPOR PHASE HYDROGEN PEROXIDE DECONTAMINATION CYCLE | HOERNER, PAUL ELLSWORTH | 1611 | §112 | Final Rejection | — | Pending | Jun 12, 2024 |
| 18674549 | INJECTION DEVICE FOR DRUG DELIVERY AND PACKAGING FOR THE INJECTION DEVICE | PATEL, SHEFALI DILIP | 3783 | §102§103 | Final Rejection | — | Pending | May 24, 2024 |
| 18712768 | STOPPER PLACEMENT IN A SYRINGE | SEIF, DARIUSH | — | §102§103§112 | Non-Final OA | — | Pending | May 23, 2024 |
| 18710112 | PLUNGER ROD REMOVAL FORCE METHOD AND FIXTURE | PATEL, SHEFALI DILIP | 3783 | §102§103§112 | Non-Final OA | — | Pending | May 14, 2024 |
| 18645779 | CONTROLLABLE DRUG DELIVERY SYSTEM AND METHOD OF USE | HALL, DEANNA K | 3783 | §102§103 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18701723 | COMPOSITION AND METHODS FOR RECOMBINANT LENTIVIRAL PRODUCTION | PRONZATI, GINA | 1633 | §103§112 | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18698098 | FC-GAMMA RECEPTOR II BINDING AND GLYCAN CONTENT | EVANS, CHRISTOPHER RYAN | 1677 | §102§103§112 | Non-Final OA | — | Pending | Apr 03, 2024 |
| 18697770 | CHARACTERIZATION APPARATUS FOR DRUG DELIVERY DEVICES OR SUBCOMPONENTS THEREOF | NATH, SUMAN KUMAR | 2855 | §101 | Non-Final OA | — | Pending | Apr 02, 2024 |
| 18696946 | Heterocyclic Compounds and Methods of Use | CHAO, ALLEN | 1622 | §103DP | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18696948 | Heterocyclic Compounds and Methods of Use | NOLAN, JASON MICHAEL | 1623 | §112 | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18611364 | ST2 ANTIGEN BINDING PROTEINS | MCCOLLUM, ANDREA K | 1674 | §101§112Other | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18685037 | MYOPEPTIDES AND METHODS OF USE IN TREATING HEART FAILURE | CHERNYSHEV, OLGA N | 1675 | §112 | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18684262 | METHODS COMPRISING THERAPEUTIC COMPOUNDS AND IN VITRO MAMMALIAN SKIN | CLARKE, TRENT R | 1651 | §101§103§112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18442665 | METHOD FOR PURIFYING PROTEINS | LOUNTOS, GEORGE THEMISTOCLIS | 1652 | §103§112DP | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18435746 | TIGIT AND CD112R BLOCKADE | GAO, ASHLEY HARTMAN | 1678 | §112 | Non-Final OA | — | Pending | Feb 07, 2024 |
| 18681252 | ISOLATION OF THERAPEUTIC PROTEIN | HOLLAND, PAUL J | 1656 | §103 | Final Rejection | — | Pending | Feb 05, 2024 |
| 18291294 | STEREOSELECTIVE PREPARATION OF TRANS HALO CYCLOBUTANE | BAKSHI, PANCHAM | 1623 | §112 | Final Rejection | — | Pending | Jan 23, 2024 |
| 18574161 | METHOD OF RECONSTITUTING LYOPHILIZED FORMULATION | BANERJEE, KOYELI | 1658 | §103 | Non-Final OA | — | Pending | Dec 26, 2023 |
| 18571614 | Treatment of Cardiovascular Disease with TREM-1 Antigen Binding Proteins | PRIEST, JESSICA MARIE | 1642 | §112DP | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18538279 | ANTIBODY CONSTRUCTS FOR MSLN AND CD3 | BRISTOL, LYNN ANNE | 1643 | §112DP | Non-Final OA | — | Pending | Dec 13, 2023 |
| 18535068 | FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME | LANDSMAN, ROBERT S | 1647 | Other | Final Rejection | 21d | Pending | Dec 11, 2023 |
| 18564805 | DRUG DELIVERY DEVICES, FINGER-GRIP ELEMENTS, AND RELATED METHODS | DOUBRAVA, JOHN A | 3783 | §102 | Final Rejection | — | Pending | Nov 28, 2023 |
| 18562107 | SOTORASIB DOSING REGIMEN | CHANDRAKUMAR, NIZAL S | 1625 | §101§103Other | Non-Final OA | 18d overdue | Pending | Nov 17, 2023 |
| 18561341 | FEEDBACK SYSTEM AND METHOD FOR A DRUG PRODUCT | CASILLASHERNANDEZ, OMAR | 2689 | §103 | Final Rejection | — | Pending | Nov 16, 2023 |
| 18289317 | DOSING REGIMEN FOR COMBINATION THERAPY TARGETING DLL3 AND PD-1 | DUTT, ADITI | 1675 | DP | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18288410 | ETELCALCETIDE FORMULATIONS | LEE, JIA-HAI | 1658 | §103§112DP | Non-Final OA | — | Pending | Oct 26, 2023 |
| 18288549 | METHOD OF OPTIMIZING A FILLING RECIPE FOR A DRUG CONTAINER | SEIF, DARIUSH | 3731 | §102§103§112 | Non-Final OA | 29d | Pending | Oct 26, 2023 |
| 18287593 | ANTI-TSLP ANTIBODY COMPOSITIONS AND USES THEREOF | MIDDLETON, DANAYA L | 1674 | §103§112DP | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18381745 | DUAL RECEPTOR ANTAGONISTIC ANTIGEN-BINDING PROTEINS AND USES THEREOF | LI, RUIXIANG | 1674 | Other | Non-Final OA | — | Pending | Oct 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAmgen Inc. has 140 pending office actions as of October 2026, spread across 52 art units and 117 examiners.
Zachary S Skelding has the most, with 4 of Amgen Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.